Point72 Europe London LLP Has $15.84 Million Stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Point72 Europe London LLP reduced its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 19.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 259,231 shares of the company’s stock after selling 61,200 shares during the period. PROCEPT BioRobotics makes up about 1.3% of Point72 Europe London LLP’s portfolio, making the stock its 22nd biggest holding. Point72 Europe London LLP’s holdings in PROCEPT BioRobotics were worth $15,836,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in PRCT. Essex Investment Management Co. LLC increased its position in PROCEPT BioRobotics by 0.6% during the 1st quarter. Essex Investment Management Co. LLC now owns 60,116 shares of the company’s stock worth $2,971,000 after buying an additional 336 shares during the period. Arizona State Retirement System increased its position in PROCEPT BioRobotics by 2.8% during the second quarter. Arizona State Retirement System now owns 12,840 shares of the company’s stock worth $784,000 after acquiring an additional 350 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in PROCEPT BioRobotics by 4.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,913 shares of the company’s stock worth $606,000 after purchasing an additional 408 shares in the last quarter. Principal Financial Group Inc. raised its stake in PROCEPT BioRobotics by 5.7% in the 4th quarter. Principal Financial Group Inc. now owns 10,588 shares of the company’s stock worth $444,000 after purchasing an additional 568 shares in the last quarter. Finally, ProShare Advisors LLC grew its position in shares of PROCEPT BioRobotics by 8.5% during the 1st quarter. ProShare Advisors LLC now owns 7,250 shares of the company’s stock worth $358,000 after purchasing an additional 570 shares in the last quarter. 89.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other PROCEPT BioRobotics news, Director Antal Rohit Desai sold 13,305 shares of PROCEPT BioRobotics stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $76.37, for a total transaction of $1,016,102.85. Following the transaction, the director now directly owns 317,518 shares of the company’s stock, valued at approximately $24,248,849.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other PROCEPT BioRobotics news, CFO Kevin Waters sold 25,000 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $82.51, for a total transaction of $2,062,750.00. Following the transaction, the chief financial officer now directly owns 96,096 shares in the company, valued at approximately $7,928,880.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Antal Rohit Desai sold 13,305 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $76.37, for a total value of $1,016,102.85. Following the transaction, the director now directly owns 317,518 shares in the company, valued at $24,248,849.66. The disclosure for this sale can be found here. Insiders have sold a total of 154,892 shares of company stock valued at $12,134,665 over the last 90 days. 17.40% of the stock is owned by insiders.

PROCEPT BioRobotics Trading Down 1.1 %

PROCEPT BioRobotics stock opened at $79.31 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 7.51 and a quick ratio of 6.49. PROCEPT BioRobotics Co. has a 52 week low of $24.83 and a 52 week high of $85.81. The stock has a fifty day moving average of $71.70 and a 200-day moving average of $63.20.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Thursday, August 1st. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.02. The firm had revenue of $53.35 million during the quarter, compared to the consensus estimate of $50.10 million. PROCEPT BioRobotics had a negative return on equity of 37.85% and a negative net margin of 58.73%. The business’s quarterly revenue was up 61.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.56) earnings per share. Equities research analysts forecast that PROCEPT BioRobotics Co. will post -1.88 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. TD Cowen lifted their price target on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Wells Fargo & Company lifted their price objective on PROCEPT BioRobotics from $67.00 to $69.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Bank of America increased their target price on PROCEPT BioRobotics from $80.00 to $94.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Finally, Truist Financial boosted their price target on PROCEPT BioRobotics from $74.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $78.17.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).